keyword
MENU ▼
Read by QxMD icon Read
search

Discontinuation of chemotherapy treatment

keyword
https://www.readbyqxmd.com/read/29143276/long-term-impact-of-temozolomide-on-1p-19q-codeleted-low-grade-glioma-growth-kinetics
#1
C Izquierdo, A Alentorn, A Idbaih, M Simó, G Kaloshi, D Ricard, M Barritault, D Meyronet, J Bruna, J Honnorat, J Y Delattre, F Ducray
Although upfront temozolomide (TMZ) has been widely-used to treat 1p/19q-codeleted diffuse low-grade gliomas (LGG), its long-term impact on the growth kinetics of these tumors has not been determined. Based on serial magnetic resonance images we retrospectively evaluated the evolution of the mean tumor diameter (MTD) in 36 progressive 1p/19q-codeleted LGG treated with upfront TMZ. After TMZ onset, all but two patients (94.4%) presented a progressive MTD decrease that lasted for a median duration of 23 months (range 3-114)...
November 15, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29142753/long-term-survival-in-a-patient-with-metastatic-squamous-cell-lung-carcinoma-a-case-report
#2
Emiddio Barletta, Piera Federico, Vincenza Tinessa, Domenico Germano, Lucia Cannella, Teresa Pironti, Bruno Daniele
Non-small-cell lung cancer (NSCLC) is the most common malignancy in industrialized countries, with a 5-year survival rate of only ~15%, as the majority of the patients have advanced-stage disease at diagnosis and the treatment options are limited. Squamous cell carcinoma the second most frequent type of NSCLC and is closely associated with cigarette smoking. We herein present the case of a 72-year-old male smoker, diagnosed with stage IV squamous cell lung carcinoma, with a solitary brain metastasis. After the diagnosis, stereotactic radiotherapy was performed on the brain metastasis...
November 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29142182/a-real-world-retrospective-cohort-study-of-combined-therapy-with-bevacizumab-and-paclitaxel-in-japanese-patients-with-metastatic-breast-cancer
#3
Hirofumi Yamada, Kenichi Inoue, Shigenori E Nagai, Maki Nakai, Fumio Arisawa, Hiroyuki Ueda, Tsuyoshi Saito, Jun Ninomiya, Toru Kuroda, Takashi Sakurai, Hitomi Kodama, Kei Kimizuka, Satoshi Hata, Toshihiro Kai, Masafumi Kurosumi
OBJECTIVE: Combined therapy with bevacizumab and paclitaxel (BP regimen) as a first-line treatment has proven highly effective with good tolerance for patients with metastatic breast cancer (MBC). The objective of this study was to examine the efficacy and safety of the BP regimen for Japanese patients with MBC in real-world clinical settings. METHODS: From June 2012 through May 2014, we recruited 94 patients at 10 medical institutions. The primary endpoint was time to treatment failure (TTF), and the secondary endpoints were overall survival (OS) and safety...
2017: Journal of Nippon Medical School, Nippon Ika Daigaku Zasshi
https://www.readbyqxmd.com/read/29130943/effect-of-a-shortened-duration-of-folfox-chemotherapy-on-the-survival-rate-of-patients-with-stage-ii-and-iii-colon-cancer
#4
Woong Bae Ji, Kwang Dae Hong, Jung-Sik Kim, Sung-Yup Joung, Jun Won Um, Byung-Wook Min
BACKGROUND: FOLFOX chemotherapy is widely used as an adjuvant treatment for advanced colon cancer. The duration of adjuvant chemotherapy is usually set to 6 months, which is based on a former study of 5-fluorouracil/leucovorin chemotherapy. However, the FOLFOX regimen is known to have complications, such as peripheral neuropathy. The aim of this study was to compare the survival rates and complications experienced by patients receiving either 4 or 6 months of FOLFOX chemotherapy. METHODS: Retrospective data analysis was performed for stage II and III patients who underwent radical resection of colon cancer...
November 2, 2017: Chemotherapy
https://www.readbyqxmd.com/read/29129441/health-related-quality-of-life-results-for-pembrolizumab-versus-chemotherapy-in-advanced-pd-l1-positive-nsclc-keynote-024-a-multicentre-international-randomised-open-label-phase-3-trial
#5
Julie R Brahmer, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O'Brien, Suman Rao, Katsuyuki Hotta, Jin Zhang, Gregory M Lubiniecki, Anne C Deitz, Reshma Rangwala, Martin Reck
BACKGROUND: In the phase 3 KEYNOTE-024 trial, treatment with pembrolizumab conferred longer progression-free survival than did platinum-based therapy in patients with treatment-naive, advanced non-small-cell lung cancer (NSCLC) with a programmed cell death-ligand 1 (PD-L1) tumour proportion score of 50% or greater (PD-L1-positive). Here we report the prespecified exploratory endpoint of pembrolizumab versus chemotherapy on patient-reported outcomes (PROs). METHODS: In this multicentre, international, randomised, open-label, phase 3 trial, we recruited patients with treatment-naive, stage IV NSCLC in 102 sites in 16 countries...
November 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29124473/severity-and-predictive-factors-of-adverse-events-in-pemetrexed-containing-chemotherapy-for-non-small-cell-lung-cancer
#6
Tsuyoshi Miyahara, Naoko Sueoka-Aragane, Kentaro Iwanaga, Norio Ureshino, Kazutoshi Komiya, Tomomi Nakamura, Chiho Nakashima, Tomonori Abe, Hisashi Matsunaga, Shinya Kimura
Pemetrexed is a key anticancer agent for treatment of advanced non-small cell lung cancer (NSCLC). Pemetrexed is generally well tolerated, but individual-patient differences exist in severity of adverse events. Our study aimed to characterize the adverse events of pemetrexed that result in discontinuation of chemotherapy and to identify risk factors associated with those adverse events. We retrospectively studied the incidence of adverse events in 257 patients with NSCLC who received pemetrexed (P) with or without bevacizumab (B) and/or carboplatin (C): P, PB, CP, or CPB...
November 9, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29121830/acute-reversible-toxic-encephalopathy-during-capecitabine-and-oxaliplatin-treatment
#7
João Godinho, Mafalda Casa-Nova, Teresa Mesquita, Maria João Baptista, Francisco Araújo, José Vale, José Luís Passos Coelho
Introduction Capecitabine is a fluoropyrimidine commonly used in the treatment of colorectal cancer which may cause central nervous system toxicity, namely cerebellar dysfunction. Case report We describe a 77-year-old man undergoing adjuvant treatment of colon cancer with capecitabine and oxaliplatin who presented with acute cerebellar ataxia and encephalopathy that progressed to coma. Diagnosis of toxic encephalopathy was made after the exclusion of alternative causes of neurological dysfunction and complete resolution of clinical findings with permanent discontinuation of chemotherapy...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29103255/-two-cases-of-urachal-carcinoma-treated-by-ts-1-cddp-as-adjuvant-chemotherapy
#8
Michinobu Ozawa, Akito Kuromoto, Kento Morozumi, Masahiko Satou, Senji Hoshi, Kenji Numahata
Case 1 : A 48-year-old man presenting with gross hematuria was suspected to have a tumor located in the bladder dome. He was referred to our department for further examination and treatment. Cystoscopy showed a dome-shaped mass in the supravesical region. Computed tomography and magnetic resonance imaging indicated the possibility of urachal carcinoma and peritoneal dissemination. Therefore, partial cystectomy with urachal resection was performed. The intraoperative findings were disseminated peritoneal nodules and mucus entering the peritoneal cavity from the tumor...
October 2017: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/29090417/long-term-clinical-remission-maintained-after-cessation-of-zidovudine-and-interferon-%C3%AE-therapy-in-chronic-adult-t-cell-leukemia-lymphoma
#9
Lucy B Cook, Aileen G Rowan, Maria A Demontis, Sophie Sagawe, Nicolas A Gillet, Anat Melamed, Claire Greiller, Aviva Witkover, Charles R M Bangham, Graham P Taylor
Globally, > 5-10 million people are estimated to be infected with Human T-lymphotropic virus type 1 (HTLV-1), of whom ~ 5% develop adult T-cell leukemia/lymphoma (ATL). Despite advances in chemotherapy, overall survival (OS) has not improved in the 35 years since HTLV-1 was first described. In Europe/USA, combination treatment with zidovudine and interferon-α (ZDV/IFN-α) has substantially changed the management of patients with the leukemic subtypes of ATL (acute or unfavorable chronic ATL) and is under clinical trial evaluation in Japan...
October 31, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29058758/features-of-921-patients-with-spinal-tuberculosis-a-16-year-investigation-of-a-general-hospital-in-southwest-china
#10
Yuan Yao, Weilin Song, Kuiyou Wang, Bingtao Ma, Huan Liu, Wenjie Zheng, Yu Tang, Yue Zhou
Southwest China has a high burden of spinal tuberculosis (TB). Few large case studies of spinal TB in southwest China have been conducted. This study investigated the features of 921 patients who were treated for spinal TB at a general hospital in southwest China between 2001 and 2016. Demographic data, clinical data, laboratory data, imaging findings, treatment methods, and outcomes of patients who were admitted to the hospital for spinal TB were reviewed retrospectively. The annual incidence of spinal TB increased throughout the study period...
October 20, 2017: Orthopedics
https://www.readbyqxmd.com/read/29050538/evaluation-of-the-head-and-neck-cancer-patient-population-and-the-incidence-of-hospitalization-at-an-academic-medical-center
#11
Lindsay A Hazelden, Matthew J Newman, Stephanie Shuey, Julie M Waldfogel, Victoria T Brown
Purpose Patients with head and neck cancer are at risk for disease- and treatment-related toxicities that may be severe enough to require hospitalization. The risk factors associated with hospitalization in these patients are not well defined. Methods We conducted a single-center, retrospective observational study of patients with head and neck cancer receiving chemotherapy at an academic medical center infusion clinic in a one-year period. The primary objective was to characterize the head and neck cancer population at an academic medical center...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29050126/-clinical-analysis-of-rituximab-induced-interstitial-lung-disease
#12
C Huang, Z W Lu, Y Q Yang, H Chen, D P Huang, H S He
Objective: To investigate the clinical characteristics, diagnosis-treatment points and prognosis of rituximab-induced interstitial lung disease (R-ILD), and to improve the recognition of this disease. Methods: The clinical data on 4 cases of R-ILD were analyzed retrospectively, and the related literatures were reviewed. The literature review was carried out respectively in Wanfang Data, CNKI and PubMed by October 2016 with"rituximab"and"interstitial lung disease"or"interstitial pneumonitis"as the search terms...
October 12, 2017: Chinese Journal of Tuberculosis and Respiratory Diseases
https://www.readbyqxmd.com/read/29038340/frontline-brentuximab-vedotin-in-combination-with-dacarbazine-or-bendamustine-in-patients-aged-%C3%A2-60-years-with-hl
#13
Jonathan W Friedberg, Andres Forero-Torres, Rodolfo E Bordoni, Vivian J M Cline, Dipti Patel Donnelly, Patrick J Flynn, Gregg Olsen, Robert Chen, Abraham Fong, Yinghui Wang, Christopher A Yasenchak
Patients aged ≥60 years with treatment-naïve Hodgkin lymphoma (HL) have few treatment options and inferior survival due to treatment-related toxicities and comorbidities. This phase 2, non-randomized, open-label study evaluated tolerability, activity, and response duration with brentuximab vedotin (BV) monotherapy (results previously reported), BV+dacarbazine (DTIC), and BV+bendamustine. Patients had classical HL and were ineligible for or declined frontline chemotherapy. Twenty-two patients received 1.8 mg/kg BV+375 mg/m(2) DTIC for up to 12 cycles, then 20 more received 1...
October 16, 2017: Blood
https://www.readbyqxmd.com/read/29033419/successful-osimertinib-rechallenge-with-steroid-therapy-after-osimertinib-induced-interstitial-lung-disease-a-case-report
#14
Tatsunori Kiriu, Daisuke Tamura, Motoko Tachihara, Reina Sekiya, Daisuke Hazama, Masahiro Katsurada, Kyosuke Nakata, Tatsuya Nagano, Masatsugu Yamamoto, Hiroshi Kamiryo, Kazuyuki Kobayashi, Yoshihiro Nishimura
A 62-year-old male with lung adenocarcinoma harboring an exon 19 deletion in the EGFR was treated with EGFR-TKIs and several cytotoxic agents. After administering a fifth-line chemotherapy regimen, a liver biopsy revealed a diagnosis of recurrence with a T790M mutation. After an 82-day course of osimertinib therapy, the patient developed osimertinib-induced interstitial lung disease (ILD). Osimertinib was discontinued, and oral prednisolone was started. The ILD quickly improved, but liver metastases progressed and osimertinib was restarted concurrently with prednisolone...
October 16, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29030300/gold-nanocage-decorated-ph-sensitive-micelle-for-highly-effective-photothermo-chemotherapy-and-photoacoustic-imaging
#15
Guoyong Zhou, Hong Xiao, Xiaoxia Li, Yi Huang, Wei Song, Liang Song, Meiwan Chen, Du Cheng, Xintao Shuai
A pH-sensitive copolymer PAsp(DIP)-b-PAsp(MEA) (PDPM) was synthesized and self-assembled to micelle loading chemotherapeutic drug doxorubicin (DOX) and introducing a gold nanocage structure for photothermo-chemotherapy and photoacoustic imaging. After further surface modification with polyethylene glycol (PEG), the DOX-loaded pH-sensitive gold nanocage (D-PGNC) around 100 nm possessed a uniform spherical structure with a pH-sensitive core of PAsp(DIP) incorporating DOX, an interlayer crosslinked via disulfide bonds and decorated with discontinuous gold shell, and a PEG corona...
December 2017: Acta Biomaterialia
https://www.readbyqxmd.com/read/29028642/-lost-to-follow-up-among-adult-cancer-survivors
#16
Amitoj Gill, Rohit Gosain, Shruti Bhandari, Rahul Gosain, Gurkirat Gill, Joseph Abraham, Kenneth Miller
BACKGROUND: Follow-up cancer care is important for patients who have received IV chemotherapy but some patients discontinue their care and are lost to follow-up (LFU) at the cancer center where they were treated. The purpose of this study was to determine what proportion of cancer survivors are LFU at 5 years after treatment, the timing of LFU, and the characteristics of those who do not continue survivorship care. METHODS: Adult patients with cancer who were treated with chemotherapy at a large community teaching hospital in 2006 and 2007 were identified and linked with State tumor registry data...
October 12, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29020960/perspectives-in-immunotherapy-meeting-report-from-the-immunotherapy-bridge-napoli-november-30th-2016
#17
Paolo A Ascierto, Bruno Daniele, Hans Hammers, Vera Hirsh, Joseph Kim, Lisa Licitra, Rita Nanda, Sandro Pignata
The complex interactions between the immune system and tumors lead the identification of key molecules that govern these interactions: immunotherapeutics were designed to overcome the mechanisms broken by tumors to evade immune destruction. After the substantial advances in melanoma, immunotherapy currently includes many other type of cancers, but the melanoma lesson is essential to progress in other type of cancers, since immunotherapy is potentially improving clinical outcome in various solid and haematologic malignancies...
October 11, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28993052/nivolumab-in-patients-with-advanced-gastric-or-gastro-oesophageal-junction-cancer-refractory-to-or-intolerant-of-at-least-two-previous-chemotherapy-regimens-ono-4538-12-attraction-2-a-randomised-double-blind-placebo-controlled-phase-3-trial
#18
Yoon-Koo Kang, Narikazu Boku, Taroh Satoh, Min-Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, Jen-Shi Chen, Kei Muro, Won Ki Kang, Kun-Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao Tamura, Keun-Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chin, Do-Youn Oh, Keiko Minashi, Jae Yong Cho, Masahiro Tsuda, Li-Tzong Chen
BACKGROUND: Patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, two or more previous regimens of chemotherapy have a poor prognosis, and current guidelines do not recommend any specific treatments for these patients. We assessed the efficacy and safety of nivolumab, a fully human IgG4 monoclonal antibody inhibitor of programmed death-1 (PD-1), in patients with advanced gastric or gastro-oesophageal junction cancer who had been previously been treated with two or more chemotherapy regimens...
October 5, 2017: Lancet
https://www.readbyqxmd.com/read/28983657/efficacy-and-safety-of-retreatment-with-nivolumab-in-metastatic-melanoma-patients-previously-treated-with-nivolumab
#19
Motoo Nomura, Atsushi Otsuka, Tomohiro Kondo, Hiroki Nagai, Yumi Nonomura, Yo Kaku, Shigemi Matsumoto, Manabu Muto
BACKGROUND: Nivolumab is a monoclonal antibody directed against programmed death-1 that has been shown to improve survival in patients with metastatic melanoma. However, the efficacy of nivolumab and other agents in melanoma remains limited. The objective of this study was to evaluate the efficacy and safety of retreatment with nivolumab in metastatic melanoma patients who previously progressed on nivolumab. PATIENTS AND METHODS: A retrospective review was performed on eight consecutive metastatic melanoma patients retreated with nivolumab who progressed on previous nivolumab...
October 5, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28983380/acute-pancreatitis-related-to-a-chemotherapy-drug
#20
Ghulam Murtaza, Anadil Faqah, Nicholas Konowitz, Hannah Lu, Aneesh Kuruvilla, Sujeen Adhikari
Drug-induced acute pancreatitis is a rare cause of pancreatitis. We present a case of pancreatitis caused by pazopanib, a tyrosine kinase inhibitor used in the treatment of renal cell carcinoma. A 57-year-old male with no risk factors for pancreatitis and a past medical history of renal cell carcinoma who was being treated with pazopanib presented with epigastric pain with radiation to the back. Lipase was elevated to 7,960 units/L. Pazopanib was discontinued on arrival and his lipase levels decreased from 7,960 to 3,380 units/L one day after discontinuation...
February 2017: World Journal of Oncology
keyword
keyword
31212
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"